USA flag logo/image

An Official Website of the United States Government

DEVELOPMENT OF AN IMAGING MARKER FOR PARKINSON'S DISEASE

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
61141
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
NS043826
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Molecular Neuroimaging, L.l.c.
60 TEMPLE STREET, SUITE 8A NEW HAVEN, CT -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: DEVELOPMENT OF AN IMAGING MARKER FOR PARKINSON'S DISEASE
Agency: HHS
Contract: 1R43NS043826-01
Award Amount: $99,755.00
 

Abstract:

DESCRIPTION (provided by applicant): The development of disease modifying agents in Parkinson's disease has rapidly expanded the need for in vivo markers for diagnosis and monitoring disease progression. Dopamine transporter (DAT) imaging offers the promise of an objective measure of dopaminergic degeneration allowing for identification of changes in the brain that occur early in the illness, prior to clinical diagnosis. The primary goal of this project is to examine the sensitivity and specificity of DAT imaging using (3-CIT and SPECT imaging as a diagnostic marker in subjects with suspected PD or PS. Neurologists will identify subjects in whom they have genuine uncertainty regarding diagnosis of PD or PS. The neurologists will be asked to document their 'best guess' diagnosis on a Diagnostic Accuracy Questionnaire at the time of referral. Subjects with suspected PD or PS will be evaluated clinically and with DAT imaging at MNI. The blinded Parkinson's expert will re-examine the subject in 6 months and make a final clinical diagnosis, which will serve as the gold standard diagnosis for each subject. The DAT imaging diagnosis will be compared to the 'gold standard' clinical diagnosis to determine the sensitivity of (3-CIT and SPECT imaging as a diagnostic marker in PD and PS. This project is a crucial step to begin to establish B-CIT and SPECT imaging as an objective diagnostic biomarker prior to definitive diagnosis.

Principal Investigator:

Danna L. Jennings
2034014300
DJENNINGS@MNIMAGING.COM

Business Contact:

Jack Mariotti
2034014300
JMARIOTTI@MNIMAGING.COM
Small Business Information at Submission:

MOLECULAR NEUROIMAGING, LLC
MOLECULAR NEUROIMAGING, LLC 60 TEMPLE ST, STE 8A NEW HAVEN, CT 06510

EIN/Tax ID: 061594851
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No